NYSE:AGE

AgeX Therapeutics News Headlines

$1.33
+0.02 (+1.53 %)
(As of 05/7/2021 11:15 AM ET)
Add
Compare
Today's Range
$1.32
$1.34
50-Day Range
$1.33
$1.90
52-Week Range
$0.67
$3.93
Volume706 shs
Average Volume309,167 shs
Market Capitalization$50.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5

Headlines

AgeX Therapeutics (NYSE AGE) News Headlines Today

SourceHeadline
AgeX Therapeutics (NYSE:AGE)  Shares Down 1.5% AgeX Therapeutics (NYSE:AGE) Shares Down 1.5%
americanbankingnews.com - May 7 at 12:10 AM
21 Stocks Moving in Mondays Pre-Market Session21 Stocks Moving in Monday's Pre-Market Session
msn.com - April 26 at 8:56 AM
AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed ValueAgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value
seekingalpha.com - April 16 at 9:01 AM
Does AgeX Therapeutics (NYSEMKT:AGE) Share Price Gain of 80% Match Its Business Performance?Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 80% Match Its Business Performance?
nasdaq.com - April 7 at 9:24 AM
BRIEF-Agex Therapeutics Reports Q4 Revenue $500,000BRIEF-Agex Therapeutics Reports Q4 Revenue $500,000
msn.com - March 31 at 6:38 PM
AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business UpdateAgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 31 at 6:38 PM
AgeX Announces Preprint Article Relating to Regeneration, Aging, and CancerAgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
finance.yahoo.com - March 12 at 11:03 AM
AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and ObesityAgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity
finance.yahoo.com - March 10 at 8:30 AM
AgeX Therapeutics and LyGenesis to Negotiate Merger AgreementAgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
finance.yahoo.com - March 2 at 8:27 AM
AgeX Therapeutics (NYSEMKT:AGE) Shareholders Booked A 40% Gain In The Last YearAgeX Therapeutics (NYSEMKT:AGE) Shareholders Booked A 40% Gain In The Last Year
finance.yahoo.com - February 3 at 9:24 AM
Where Do Hedge Funds Stand On AgeX Therapeutics, Inc. (AGE)?Where Do Hedge Funds Stand On AgeX Therapeutics, Inc. (AGE)?
finance.yahoo.com - November 27 at 9:19 PM
AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateAgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 16 at 7:29 PM
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress SyndromeAgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
finance.yahoo.com - October 28 at 9:25 AM
Juvenescence discloses 50% stake in AgeX TherapeuticsJuvenescence discloses 50% stake in AgeX Therapeutics
seekingalpha.com - October 8 at 12:00 PM
LCTX Mar 2021 5.000 callLCTX Mar 2021 5.000 call
uk.finance.yahoo.com - October 1 at 9:49 AM
Prescott General Partners LLC Buys Vapotherm Inc, AgeX Therapeutics IncPrescott General Partners LLC Buys Vapotherm Inc, AgeX Therapeutics Inc
finance.yahoo.com - September 9 at 11:41 PM
AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic PurposesAgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
businesswire.com - September 9 at 8:16 AM
Reflecting on AgeX Therapeutics (NYSEMKT:AGE) Share Price Returns Over The Last YearReflecting on AgeX Therapeutics' (NYSEMKT:AGE) Share Price Returns Over The Last Year
finance.yahoo.com - August 7 at 8:22 AM
Reflecting on AgeX Therapeutics' (NYSEMKT:AGE) Share Price Returns Over The Last YearReflecting on AgeX Therapeutics' (NYSEMKT:AGE) Share Price Returns Over The Last Year
finance.yahoo.com - August 7 at 8:22 AM
54 Stocks Moving in Wednesdays Pre-Market Session54 Stocks Moving in Wednesday's Pre-Market Session
msn.com - August 5 at 10:10 AM
AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic ...AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic ...
www.businesswire.com - June 16 at 2:57 PM
BRIEF-Agex Therapeutics And Pluristyx Announce Manufacturing, Marketing, And Distribution DealBRIEF-Agex Therapeutics And Pluristyx Announce Manufacturing, Marketing, And Distribution Deal
in.reuters.com - June 16 at 9:57 AM
AgeX broadens access to stem cell lines with Pluristyx dealAgeX broadens access to stem cell lines with Pluristyx deal
seekingalpha.com - June 16 at 9:57 AM
AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic ApplicationsAgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
finance.yahoo.com - June 16 at 9:57 AM
AgeX Therapeutics Receives Stock Exchange Deficiency LetterAgeX Therapeutics Receives Stock Exchange Deficiency Letter
finance.yahoo.com - June 5 at 6:17 PM
BRIEF-AgeX Therapeutics And ImStem Biotechnology Sign Non-Binding Letter Of IntentBRIEF-AgeX Therapeutics And ImStem Biotechnology Sign Non-Binding Letter Of Intent
www.reuters.com - June 3 at 12:46 AM
AgeX Expands Relationship With ImStem Regarding IMS001 To Include COVID-19, ARDSAgeX Expands Relationship With ImStem Regarding IMS001 To Include COVID-19, ARDS
www.nasdaq.com - June 2 at 9:45 AM
AgeX Therapeutics +12% on ESI 053 deal for COVID-19AgeX Therapeutics +12% on ESI 053 deal for COVID-19
seekingalpha.com - June 2 at 9:45 AM
AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDSAgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
finance.yahoo.com - June 2 at 9:45 AM
BRIEF-Agex Appoints Andrea Park As Chief Financial OfficerBRIEF-Agex Appoints Andrea Park As Chief Financial Officer
www.reuters.com - May 21 at 11:07 PM
New finance chief at AgeX TherapeuticsNew finance chief at AgeX Therapeutics
seekingalpha.com - May 21 at 1:06 PM
AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial OfficerAgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer
finance.yahoo.com - May 21 at 1:06 PM
AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business UpdateAgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
www.businesswire.com - May 14 at 5:35 PM
AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced PluripotentAgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent
www.bloomberg.com - May 12 at 8:15 PM
BRIEF-Agex Therapeutics Announces Reduction In Projected Cash ExpendituresBRIEF-Agex Therapeutics Announces Reduction In Projected Cash Expenditures
www.reuters.com - May 1 at 6:42 PM
AgeX Therapeutics Announces Reduction in Projected Cash ExpendituresAgeX Therapeutics Announces Reduction in Projected Cash Expenditures
finance.yahoo.com - May 1 at 6:42 PM
AgeX Therapeutics reports FY resultsAgeX Therapeutics reports FY results
seekingalpha.com - March 30 at 7:17 PM
AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business UpdateAgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 30 at 6:45 PM
AgeX licensee on go to start study of cell therapy in MS; shares up 5%AgeX licensee on go to start study of cell therapy in MS; shares up 5%
seekingalpha.com - March 20 at 12:09 PM
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple SclerosisAgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
finance.yahoo.com - March 20 at 12:09 PM
AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian CellsAgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells
finance.yahoo.com - February 28 at 9:25 AM
The AgeX Therapeutics (NYSEMKT:AGE) Share Price Is Down 65% So Some Shareholders Are Wishing They SoldThe AgeX Therapeutics (NYSEMKT:AGE) Share Price Is Down 65% So Some Shareholders Are Wishing They Sold
finance.yahoo.com - February 9 at 2:09 PM
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological DisordersAgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders
finance.yahoo.com - February 3 at 9:00 AM
AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic CellsAgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells
finance.yahoo.com - January 29 at 8:09 AM
AgeX Therapeutics IncAgeX Therapeutics Inc
www.bloomberg.com - January 24 at 8:59 PM
AgeX Therapeutics anticipates a revolution in aging in next 10 yearsAgeX Therapeutics anticipates a 'revolution' in aging in next 10 years
www.proactiveinvestors.com - January 16 at 12:19 AM
AgeX Therapeutics to Participate at Four Conferences in January 2020AgeX Therapeutics to Participate at Four Conferences in January 2020
finance.yahoo.com - January 14 at 8:20 AM
AgeX announces drawdown of second tranche of loan facilityAgeX announces drawdown of second tranche of loan facility
seekingalpha.com - December 26 at 12:38 PM
AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd.AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd.
www.businesswire.com - December 26 at 8:28 AM
AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem CellsAgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
finance.yahoo.com - December 10 at 8:27 AM
This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.